about
Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaquesMechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applicationsEvidence for IFN-gamma up- and IL-4 downregulation late post-transplant in patients with good kidney graft outcome.Association of high IFN-gamma plasma levels with low B-cell counts in renal transplant recipients with stable long-term graft function.Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/- mice after pharmacological immunosuppression.Gingyo-san enhances immunity and potentiates infectious bursal disease vaccination.Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade.Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.Immunosuppressive therapies in myasthenia gravis.EFNS/ENS Guidelines for the treatment of ocular myasthenia.Immunosuppressive drugs in whole blood: validation of a commercially available liquid chromatography/tandem mass spectrometry kit and comparison with immunochemical assays.Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.Oral low-dose tacrolimus therapy for refractory hemophagocytic syndrome associated with systemic lupus erythematosus.FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.On-target and direct modulation of alloreactive T cells by a nanoparticle carrying MHC alloantigen, regulatory molecules and CD47 in a murine model of alloskin transplantation.
P2860
Q27305046-5F27F94F-8473-4A10-A0EE-4B5651C479BBQ28282507-FE30C3F9-BBAF-4F18-843C-65E93AC41F46Q33291448-1AE96024-C1C2-4BF8-9642-9DFF763293CEQ33497475-C0C4F253-64FF-4CCF-8907-26B94D66F0CDQ34086937-F9799A17-CF17-43BE-8EEA-C51ACB4ACB07Q34983952-097A5146-1C9E-4A27-A695-A71F7B80CD23Q36011368-E336F959-654F-44E7-A438-4EE571247250Q36122631-D5A3D3EF-CE32-4741-85F3-647A651D501CQ37462768-6C6ADEE9-EEDD-4171-8228-F83E5C4A4C47Q37694576-E9A942C0-6670-48EF-A51B-7A907997E529Q38182650-9D717A7F-BC0B-4D5C-974E-E4E349B608FFQ38821531-267392FA-3821-40EB-A1CA-26A0805C84E9Q38970893-79663ACC-E577-4AD1-89FD-C5CD570261C5Q40319856-CAB1A286-A5E5-4105-99A9-23E9C51ECF51Q50734762-144E0446-EDE1-4171-B862-1F50314992C6Q52366029-2062E346-E580-4EC8-9ECB-CF3F9F1792A3
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The mosaic of immunosuppressive drugs.
@ast
The mosaic of immunosuppressive drugs.
@en
The mosaic of immunosuppressive drugs.
@nl
type
label
The mosaic of immunosuppressive drugs.
@ast
The mosaic of immunosuppressive drugs.
@en
The mosaic of immunosuppressive drugs.
@nl
prefLabel
The mosaic of immunosuppressive drugs.
@ast
The mosaic of immunosuppressive drugs.
@en
The mosaic of immunosuppressive drugs.
@nl
P1433
P1476
The mosaic of immunosuppressive drugs.
@en
P2093
Marwan A Masri
P304
P356
10.1016/S0161-5890(03)00075-0
P577
2003-07-01T00:00:00Z